Skip to main content
PharmaEssentia Corporation logo

PharmaEssentia Corporation — Investor Relations & Filings

Ticker · 6446 ISIN · TW0006446008 LEI · 54930001GNQLDIFASK68 TW Manufacturing
Open in API
Filings indexed 32 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 6446

About PharmaEssentia Corporation

http://www.PharmaEssentia.com

PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.

Recent filings

Filing Released Lang Actions
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document is a Q1 filing (“115年1季申報作業”) on Taiwan’s MOPS platform for a listed company, containing actual interim financial data (investment balances, equity method results) rather than just an announcement or link to a report. This fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure (公開資訊觀測站) by a Taiwan‐listed company detailing its direct and indirect investments in Mainland China for the period (年度115, 季別01). It is a specific compliance table of cross‐strait investment amounts, approved limits, repatriated gains, etc. There are no full financial statements, narrative MD&A or earnings highlights—just a compliance schedule. This falls under general regulatory filings rather than a standalone financial report, presentation, or management notice. Therefore it should be classified as Regulatory Filings (RNS).
2026-05-13 Chinese
115年第1季權益變動表
Regulatory Filings Classification · 95% confidence The provided text is an error message notifying that the page cannot be accessed, with no substantive corporate or financial content. It does not match any specific filing type definitions. As such, it falls into the fallback category of miscellaneous regulatory communications.
2026-05-13 Chinese
115年第1季現金流量表
Interim / Quarterly Report Classification · 90% confidence The document provides a detailed consolidated cash flow statement for the first quarter of the company’s fiscal year (Minguo 115/Q1 and comparative Q1 Minguo 114). It contains actual financial statement line items and figures rather than a summary announcement or link to a report. This aligns with an interim/quarterly report containing substantive financial data rather than a simple earnings highlight or an announcement. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-13 Chinese
115年第1季綜合損益表
Interim / Quarterly Report Classification · 90% confidence The document is a detailed consolidated income statement (合併綜合損益表) for the company’s first quarter (Q1) period, with substantive financial data (revenues, costs, expenses, EPS, etc.). This meets the criteria for an Interim/Quarterly Report containing actual financial statements. It is not just an announcement or summary, but the report itself. Therefore, it should be classified as IR (Interim/Quarterly Report). Q1 2026
2026-05-13 Chinese
115年第1季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document is the full consolidated balance sheet for the first quarter (Q1) of Year 115 (民國115年第1季) with actual financial statement line items (assets, liabilities, equity) for 115/03/31, 114/12/31, and 114/03/31. It is substantive financial data and therefore represents an Interim / Quarterly Report, not merely an announcement or a highlights summary. Q1 2026
2026-05-13 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.